CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jenburkt Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jenburkt Pharmaceuticals Ltd
Nirmala Apartments
93, J. P. Road,, Andheri (West)
Phone: +91 2267603603p:+91 2267603603 MUMBAI, 400058  India Ticker: 524731524731
Business Summary
Jenburkt Pharmaceuticals Limited is an India-based company that is engaged in the business of manufacturing, producing, developing and marketing a range of branded pharmaceuticals and health care products. The Company offers pharmaceutical products for various therapeutic areas, analgesic and antipyretics anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer division, cough and cold, muscle relaxants neuropathic pain, nutraceuticals and pain management. The Company's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets and others. The Company's manufacturing plant is located in Sihor-Gujarat. The Company's products are exported to approximately 13 countries globally.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman, Managing Director Ashish U.Bhuta 47 7/16/2013 6/7/2007
Whole Time Director, Chief Financial Officer Dilip H.Bhuta 71 4/1/2019 7/16/2013
Compliance Officer, Company Secretary Ashish R.Shah
4 additional Officers and Directors records available in full report.

Business Names
Business Name
524731
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd(NDA)

General Information
Number of Employees: 724 (As of 3/31/2023)
Outstanding Shares: 4,413,300 (As of 9/30/2023)
Shareholders: 5,721
Stock Exchange: BOM
Fax Number: +91 2266943123


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024